Matteo Dugo

Computational biologist working on breast cancer at IRCCS Ospedale San Raffaele - Milan

[Matteo Dugo @DugoMat]

TROP2 remains a key therapeutic target across tumor types, but its biology is more complex than expression alone suggests. This multi-omic study provides a broader framework to interpret TACSTD2 across cancers. Well done @NotiniGiulia and all co-authors.

[Giulia Notini @NotiniGiulia]

🧵 1/10

Do you know everything about Trop2? 🤔

In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.

🔗https://t.co/WhTZRfT62R

[Matteo Dugo @DugoMat]

12 / 12
🙏 This would not have been possible without Fondazione Michelangelo, @FondazioneBona1, @SanRaffaeleMI, and funders @AIRC_it @BCRFcure. A special thank to all collaborators who made this work possible!

[Matteo Dugo @DugoMat]

📣New work from the NeoTRIPaPDL1 trial led by @BianchiniGP out now in @Annals_Oncology!

We profiled tumor gene expression before AND during neoadjuvant chemo ± atezolizumab (ICI) in TNBC to find predictors of pCR: https://t.co/yeGIUoKtqF

Key findings👇 #TNBC #immunotherapy

[Matteo Dugo @DugoMat]

🗂️ All data are publicly available!

One of the largest longitudinal RNA-Seq datasets from a phase III RCT in TNBC.

📦Data: NCBI GEO GSE319641
💻 Code: https://t.co/2khhz8gifp

Validate, challenge, build on it. #OpenScience